[{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"FSHD Society","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ FSHD Society","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ FSHD Society"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Therapeutics \/ MyoKardia"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Fulcrum Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
